Respiratory diseases in children: possibilities for correcting peroxide homeostasis

Background. The article reflects modern ideas about the course of lipid peroxidation processes in bronchitis in children. Much attention is paid to such markers of peroxide homeostasis as malondialdehyde (MDA) and antioxidant activity (AOA). The experience of using natural metabolites of the Krebs cycle to correct peroxide homeostasis is summarized. The data of authors’ own research on the use of dietary supplements based on salts of succinic and fumaric acids as antioxidants in the complex therapy of respiratory pathology in children are presented. Objective. Identification of the features of the dynamics of the MDA and AOA levels in children with bronchitis as a result of various lines of therapy. Methods. The study involved 52 children aged 7 to 14 years who underwent inpatient treatment at the Clinic of the Kazan Medical University. Children were divided into two groups. First group included 29 children who received the traditional regimen of therapy. The second group consisted of 23 children whose treatment was supplemented with potassium fumarate. Results. It has been shown that in the acute period of the disease, disadaptation processes characterized by a significant decrease in the AOA level and an increase in MDA level are developing. It was noted that by the time of clinical recovery, there was no significant normalization of the level of these indicators against the background of traditional therapy. The inclusion of potassium fumarate as an antioxidant in the complex therapy managed to significantly reduce the MDA level and increase the AOA level. Conclusion. Potassium fumarate was well tolerated without side and allergic reactions. The authors substantiate the possibility of using potassium fumarate in children with bronchitis for normalizing peroxide homeostasis. The inclusion of agents with antioxidant properties in the complex of pathogenetic correction of bronchopulmonary pathology in children, according to the authors, will optimize the tactics of managing patients with this pathology both at the outpatient and inpatient stages of treatment.

bronchitis, antioxidant activity, malondialdehyde, fumaric acid